An experimental antibiotic was able to prevent recurrent Clostridioides difficile infections (rCDI) by killing bacterial spores as well as growing spores. Researchers from the University of Notre Dame reported their findings in the Proceedings of the National Academy of Sciences on May 8, 2023.
Amgen Inc. and Tscan Therapeutics Inc. have entered into a multi-year collaboration that will use Tscan’s proprietary target discovery platform, Targetscan, to identify the antigens recognized by T cells in patients with Crohn’s disease.
Tscan Therapeutics Inc.’s Wall Street-pleasing deal with Amgen Inc. in Crohn’s disease (CD) could expand into ulcerative colitis, but meanwhile is bringing $30 million up front with the potential for more than $500 million in preclinical, clinical, regulatory and commercial milestone payments, plus tiered single-digit royalties. Shares of Waltham, Mass.-based Tscan (NASDAQ:TCRX) closed May 9 at $3.40, up $1.25, or 58%, as the world learned of the multiyear collaboration with Amgen, of Thousand Oaks, Calif., that will use Tscan’s target discovery platform, Targetscan, to identify the antigens recognized by T cells in patients with CD.
There is still a lack of specific biomarkers in biliary epithelial cells of patients with primary sclerosing cholangitis (PSC). Investigators from the...
Esophageal remodeling occurs during the development of eosinophilic esophagitis (EoE); syndecan-1, also known as CD138, is a cell surface marker involved in extracellular remodeling and it has been shown to be differentially expressed in tissue from patients with EoE compared to healthy esophageal tissue. University of North Carolina at Chapel Hill researchers conducted studies to validate serum CD138 levels as a noninvasive tool for the diagnosis of EoE.
Buoyed by the progress it has made with its lead integrin therapy for moderate to severe ulcerative colitis, MORF-057, which significantly reduced disease activity in a phase IIa trial, Morphic Therapeutic Inc. is raising $240 million in a public offering to further advance the candidate through the clinic.
A pill that delivers electrical stimulation to the vagus nerve from inside the stomach was able to trigger the release of appetite-controlling neurohormones, specifically the “hunger hormone” ghrelin. The work, which was described in the April 26, 2023, issue of Science Robotics, could pave the way for treating “metabolic, [gastrointestinal], and neuropsychiatric disorders noninvasively with minimal off-target effects,” the authors wrote in their paper.
A pill that delivers electrical stimulation to the vagus nerve from inside the stomach was able to trigger the release of appetite-controlling neurohormones, specifically the “hunger hormone” ghrelin.
RSS
